Theravance Biopharma
- Country
- Ownership
- -
- Employees
- 99
- Market Cap
- -
- Introduction
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded i...
Phase 2 Study of TD-9855 to Treat Fibromyalgia
- Conditions
- Interventions
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 392
- Registration Number
- NCT01693692
- Locations
- 🇺🇸
Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸PAB Clinical Research, Brandon, Florida, United States
TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 47
- Registration Number
- NCT01655771
- Locations
- 🇺🇸
ICON Development Solutions, San Antonio, Texas, United States
A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 16
- Registration Number
- NCT01644240
- Locations
- 🇺🇸
Miami Research Associates, Miami, Florida, United States
A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 20
- Registration Number
- NCT01568411
- Locations
- 🇺🇸
Icon Development Services, San Antonio, Texas, United States
Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 40
- Registration Number
- NCT01467726
- Locations
- 🇺🇸
Comprehensive Clinical Development, Miramar, Florida, United States
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 217
- Registration Number
- NCT01459926
- Locations
- 🇺🇸
G and L Research, LLC, Foley, Alabama, United States
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 295
- Registration Number
- NCT01458340
- Locations
- 🇺🇸
Psychiatric Associates, Overland Park, Kansas, United States
🇺🇸Florida Clinical Research Center, LLC, Bradenton, Florida, United States
🇺🇸Florida Clinical Research Center, Maitland, Florida, United States
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 95
- Registration Number
- NCT01401985
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Pasadena, California, United States
A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 69
- Registration Number
- NCT01333540
- Locations
- 🇺🇸
Clinical Research Unit, Salt Lake City, Utah, United States
A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 102
- Registration Number
- NCT01040637
- Locations
- 🇺🇸
Clinical Research Unit, Salt Lake City, Utah, United States